Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Ovarian Cancer | Research

Nomogram for predicting lymph node metastasis in patients with ovarian cancer using ultrasonography: a multicenter retrospective study

Authors: Yaqin Yang, Xuewei Ye, Binqian Zhou, Yang Liu, Mei Feng, Wenzhi Lv, Dan Lu, Xinwu Cui, Jianxin Liu

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Ovarian cancer is a common cancer among women globally, and the assessment of lymph node metastasis plays a crucial role in the treatment of this malignancy. The primary objective of our study was to identify the risk factors associated with lymph node metastasis in patients with ovarian cancer and develop a predictive model to aid in the selection of the appropriate surgical procedure and treatment strategy.

Methods

We conducted a retrospective analysis of data from patients with ovarian cancer across three different medical centers between April 2014 and August 2022. Logistic regression analysis was employed to establish a prediction model for lymph node metastasis in patients with ovarian cancer. We evaluated the performance of the model using receiver operating characteristic (ROC) curves, calibration plots, and decision analysis curves.

Results

Our analysis revealed that among the 368 patients in the training set, 101 patients (27.4%) had undergone lymph node metastasis. Maximum tumor diameter, multifocal tumor, and Ki67 level were identified as independent risk factors for lymph node metastasis. The area under the curve (AUC) of the ROC curve in the training set was 0.837 (95% confidence interval [CI]: 0.792–0.881); in the validation set this value was 0.814 (95% CI: 0.744–0.884). Calibration plots and decision analysis curves revealed good calibration and clinical application value.

Conclusions

We successfully developed a model for predicting lymph node metastasis in patients with ovarian cancer, based on ultrasound examination results and clinical data. Our model accurately identified patients at high risk of lymph node metastasis and may guide the selection of appropriate treatment strategies. This model has the potential to significantly enhance the precision and efficacy of clinical management in patients with ovarian cancer.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Desteli GA, Gultekin M, Usubutun A, Yuce K, Ayhan A. Lymph node Metastasis in grossly apparent clinical stage Ia epithelial Ovarian cancer: Hacettepe experience and review of literature. World J Surg Oncol. 2010;8:106.CrossRefPubMedPubMedCentral
3.
Duska LR, Kohn EC. The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications. Ann Oncol 2017, 28(suppl_8).
4.
Dell’ Anna T, Signorelli M, Benedetti-Panici P, Maggioni A, Fossati R, Fruscio R, Milani R, Bocciolone L, Buda A, Mangioni C, et al. Systematic lymphadenectomy in Ovarian cancer at second-look Surgery: a randomised clinical trial. Br J Cancer. 2012;107(5):785–92.CrossRefPubMedPubMedCentral
5.
Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim J-W, Raspagliesi F, Lampe B, Aletti G, et al. A Randomized Trial of Lymphadenectomy in patients with Advanced Ovarian Neoplasms. N Engl J Med. 2019;380(9):822–32.CrossRefPubMed
6.
Morice P, Joulie F, Camatte S, Atallah D, Rouzier R, Pautier P, Pomel C, Lhommé C, Duvillard P, Castaigne D. Lymph node involvement in epithelial Ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg. 2003;197(2):198–205.CrossRefPubMed
7.
Yuan Y, Gu Z-X, Tao X-F, Liu S-Y. Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with Ovarian cancer: a meta-analysis. Eur J Radiol. 2012;81(5):1002–6.CrossRefPubMed
8.
Chen H-Z, Wang X-R, Zhao F-M, Chen X-J, Li X-S, Ning G, Guo Y-K. The Development and Validation of a CT-Based Radiomics Nomogram to Preoperatively Predict Lymph Node Metastasis in High-Grade Serous Ovarian Cancer. Front Oncol. 2021;11:711648.CrossRefPubMedPubMedCentral
9.
Moro F, Verdecchia V, Romeo P, Ciccarone F, Zannoni GF, Valentin L, Timmerman D, Bourne T, Froyman W, Scambia G, et al. Ultrasound, macroscopic and histological features of malignant ovarian tumors. Int J Gynecol Cancer. 2021;31(1):150–1.CrossRefPubMed
10.
Heremans R, Valentin L, Sladkevicius P, Timmerman S, Moro F, Van Holsbeke C, Epstein E, Testa AC, Timmerman D, Froyman W. Imaging in gynecological Disease (24): clinical and ultrasound characteristics of ovarian mature cystic teratomas. Ultrasound Obstet Gynecol. 2022;60(4):549–58.CrossRefPubMed
11.
Gottschau M, Rosthøj S, Settnes A, Aalborg GL, Viuff JH, Munk C, Jensen A, Kjær SK, Mellemkjær L. Long-Term Health Consequences After Ovarian Removal at Benign Hysterectomy: A Nationwide Cohort Study. Annals of internal medicine 2023.
12.
Wei X, Oxley S, Sideris M, Kalra A, Brentnall A, Sun L, Yang L, Legood R, Manchanda R. Quality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis. Am J Obstet Gynecol 2023.
13.
Åkesson Ã, Adok C, Dahm-Kähler P. Increased survival in non-endometrioid endometrial cancer after introducing lymphadenectomy and tailoring radiotherapy - A population-based cohort study. Eur J Cancer. 2022;169:54–63.CrossRefPubMed
14.
Wetterwald L, Sarivalasis A, Liapi A, Mathevet P, Achtari C. Lymph node involvement in recurrent Serous Borderline ovarian tumors: current evidence, controversies, and a review of the literature. Cancers (Basel) 2023, 15(3).
15.
Yu H, Wang J, Wu B, Li J, Chen R. Prognostic significance and risk factors for pelvic and para-aortic lymph node Metastasis in type I and type II Ovarian cancer: a large population-based database analysis. J Ovarian Res. 2023;16(1):28.CrossRefPubMedPubMedCentral
16.
Caruso G, Palaia I, Bogani G, Tomao F, Perniola G, Benedetti Panici P, Muzii L, Di Donato V. Systematic lymph node dissection during interval debulking Surgery for advanced epithelial Ovarian cancer: a systematic review and meta-analysis. J Gynecol Oncol. 2022;33(5):e69.CrossRefPubMedPubMedCentral
17.
Kleppe M, Wang T, Van Gorp T, Slangen BFM, Kruse AJ, Kruitwagen RFPM. Lymph node Metastasis in stages I and II Ovarian cancer: a review. Gynecol Oncol. 2011;123(3):610–4.CrossRefPubMed
18.
Viveros-Carreño D, Rodriguez J, Pareja R. Incidence of lymph node Metastasis in early-stage low-grade serous Ovarian cancer: a systematic review. Int J Gynecol Cancer 2022.
19.
Forstner R. Radiological staging of Ovarian cancer: imaging findings and contribution of CT and MRI. Eur Radiol. 2007;17(12):3223–35.CrossRefPubMed
20.
Xiang H, Yang F, Zheng X, Pan B, Ju M, Xu S, Zheng M. A Nomogram for Preoperative Prediction of the risk of Lymph Node Metastasis in patients with epithelial Ovarian Cancer. Curr Oncol. 2023;30(3):3289–300.CrossRefPubMedPubMedCentral
21.
Zhou J, Sun J-Y, Wu S-G, Wang X, He Z-Y, Chen Q-H, Li F-Y. Risk factors for lymph node Metastasis in Ovarian cancer: implications for systematic lymphadenectomy. Int J Surg. 2016;29:123–7.CrossRefPubMed
22.
Powless CA, Aletti GD, Bakkum-Gamez JN, Cliby WA. Risk factors for lymph node Metastasis in apparent early-stage epithelial Ovarian cancer: implications for surgical staging. Gynecol Oncol. 2011;122(3):536–40.CrossRefPubMed
23.
Ulker V, Kuru O, Numanoglu C, Akbayır O, Polat I, Uhri M. Lymph node Metastasis in patients with epithelial Ovarian cancer macroscopically confined to the ovary: review of a single-institution experience. Arch Gynecol Obstet. 2014;289(5):1087–92.CrossRefPubMed
24.
Zhang L, Guan Z, Yin Y, Ou C, Qian H, Tang M, Shen A. Predictive value of indicator of CA125 combined with D-dimer (ICD) for lymph node Metastasis in patients with Ovarian cancer: a two center cohort study. J Cancer. 2022;13(8):2447–56.CrossRefPubMedPubMedCentral
25.
Wang J, Chen S, Zhong F, Zhu T, Zhao Y. A LASSO-derived prediction model for assessing the risk of lymph node Metastasis in T1 and T2 epithelial Ovarian cancer: an international retrospective cohort study. Int J Surg 2023.
26.
Benedetti Panici P, Giannini A, Fischetti M, Lecce F, Di Donato V. Lymphadenectomy in Ovarian Cancer: is it still justified? Curr Oncol Rep. 2020;22(3):22.CrossRefPubMed
27.
Anglesio MS, Bashashati A, Wang YK, Senz J, Ha G, Yang W, Aniba MR, Prentice LM, Farahani H, Li Chang H, et al. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. J Pathol. 2015;236(2):201–9.CrossRefPubMedPubMedCentral
28.
Bliss JM, Tovey H, Evans A, Holcombe C, Horgan K, Mallon E, Vidya R, Skene A, Dodson A, Hills M, et al. Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + Breast cancer: further results from the POETIC trial (CRUK/07/015). Breast Cancer Res. 2023;25(1):39.CrossRefPubMedPubMedCentral
29.
Baněčková M, Thompson LDR, Hyrcza MD, Vaněček T, Agaimy A, Laco J, Simpson RHW, Di Palma S, Stevens TM, Brcic L et al. Salivary gland secretory carcinoma: clinicopathologic and genetic characteristics of 215 cases and proposal for a Grading System. Am J Surg Pathol 2023.
Metadata
Title
Nomogram for predicting lymph node metastasis in patients with ovarian cancer using ultrasonography: a multicenter retrospective study
Authors
Yaqin Yang
Xuewei Ye
Binqian Zhou
Yang Liu
Mei Feng
Wenzhi Lv
Dan Lu
Xinwu Cui
Jianxin Liu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11624-5

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Mechanism of prognostic marker SPOCK3 affecting malignant progression of prostate cancer and construction of prognostic model

Research

Relationship between PIWIL1 gene polymorphisms and epithelial ovarian cancer susceptibility among southern Chinese woman: a three-center case–control study

Research

Nomogram incorporating Epstein-Barr virus DNA and a novel immune-nutritional marker for survival prediction in nasopharyngeal carcinoma

Research

The combination of PD-L1 expression and the neutrophil-to-lymphocyte ratio as a prognostic factor of postoperative recurrence in non-small-cell lung cancer: a retrospective cohort study

Study Protocol

Study protocol for a multicenter randomised controlled trial on the (cost)effectiveness of biopsy combined with same-session MR-guided LITT versus biopsy alone in patients with primary irresectable glioblastoma (EMITT trial)

Research

Automated breast volume scanner based Radiomics for non-invasively prediction of lymphovascular invasion status in breast cancer

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits